Taysha Gene Therapies
TSHA
46 hedge funds and large institutions have $367M invested in Taysha Gene Therapies in 2020 Q3 according to their latest regulatory filings, with 46 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
46.3% more ownership
Funds ownership: 0% → 46.3% (+46%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$99M |
| 2 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
+$47M |
| 3 |
BlackRock
New York
|
+$43.3M |
| 4 |
AG
Artal Group
Luxembourg
|
+$26.8M |
| 5 |
CC
Casdin Capital
New York
|
+$19.3M |
Top Sellers
TSHA Hedge Fund Activity: Q3 2020 in Review
46 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q3 2020, worth a combined $367M.
Buyers outnumbered sellers: 46 funds opened new TSHA positions and 0 closed out — a net gain of 46 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $99M.
- 46 institutional investors held Taysha Gene Therapies (TSHA) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $367M of Taysha Gene Therapies stock for Q3 2020.
- 46 funds opened new Taysha Gene Therapies positions in Q3 2020 and 0 closed out, a net change of +46 holders.
- The largest Taysha Gene Therapies buyer in Q3 2020 was Fidelity Investments, an estimated $99M added.
Based on aggregated 13F filings for Q3 2020.